Grais Linda 4

What Happened Linda Grais, a director of Corvus Pharmaceuticals, was granted a derivative equity award covering 15,000 shares on June 11, 2026. The grant is reported at $0.00 (no cash paid at grant) and is marked as a derivative award (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (4 days after the transaction).
• Security: derivative award for 15,000 underlying shares; reported price $0.00.
• Vesting: The underlying shares subject to the option vest and become exercisable 100% on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting, assuming continuous service as a director. (Footnote from filing.)
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: The Form 4 was filed 6/15/2026 for a 6/11/2026 transaction (4-day gap); Form 4s are normally due within two business days, so this appears delayed.

Context This was a director equity grant (derivative award) rather than a market purchase or sale. The award does not appear to be immediately exercisable — it vests in full on the earlier of the first anniversary or the 2027 annual meeting, subject to continued service. Director grants like this are commonly part of compensation arrangements and do not, by themselves, indicate buying or selling pressure.